



2500 Meadowpine Blvd.
Unit 202, Mississauga, ON L5N 6C4
Ph: (416) 669-9392
Email: ir@sirebioscience.com
www.sirebioscience.com

Sire Bioscience Announces Consolidation

Toronto, Ontario, September 18, 2020 – Sire Bioscience Inc. (“SIRE”) (CSE:SIRE) (OTC:BLLXF) (FSE:BR1B) (“Sire” or the “Company”) announces that it intends to complete a consolidation of its issued and outstanding common shares (the “Shares”) on the basis of one (1) new Share for every ten (10) Shares currently held. A new CUSIP and ISIN number will be issued.

Registered shareholders will receive a letter of transmittal from the Company’s transfer agent, Computershare Investor Services Inc., with instructions for exchanging their pre-consolidated Shares. Shareholders who hold their Shares through a broker or other intermediary and do not have Shares registered in their name, will not need to complete a letter of transmittal.

About Sire Bioscience Inc.

SIRE's principal business activity is to engage in the investment, production of, development of hemp, CBD and non-CBD products. SIRE has its wholly-owned facility in Leamington, Ontario. The land parcel includes 50 acres of prime horticultural land, with a 160,000 sq. ft. facility of combined greenhouse and indoor space. SIRE's goal is to become a vertically integrated CPG life science company with its "House of Brands" offering.

SIRE is headquartered in Mississauga, Ontario and is managed by a group of successful entrepreneurs who have extensive experience in the areas of consumer packaged goods, manufacturing, logistics, and distribution.

FOR INFORMATION, CONTACT:

Sire Bioscience Inc.

E: ir@sirebioscience.com

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.